RKI expects vaccine against SARS-CoV-2 by early 2021

Donnerstag, 27. August 2020

/picture alliance

Berlin - The Robert Koch Institute (RKI) expects vaccines against the SARS-CoV-2 coronavirus to be available at the beginning of next year. This emerges from the latest epidemiological bulletin.

According to the current state of knowledge, it is expected that one or more COVID-19 vaccine (s) could be approved in the European Union and the first production batches distributed and marketed by the beginning of 2021, "it says.

However, it is to be expected that enough vaccine will not be available for the entire population from the outset. Therefore, the Standing Vaccination Commission should develop a concept of how the then available stocks could be used with the best possible benefit.

on the subject

Epidemiological Bulletin
aerzteblatt.de

Corona: Germany no longer relies on its own vaccine procurement
Risk groups: RKI rates the risk situation as "very high"
SARS-CoV-2: RKI does not expect a vaccine in autumn
This principle is called prioritization. Ethical aspects are particularly important for fair distribution. The prioritization should ensure that the best possible contribution to the avoidance of serious illnesses and deaths.

As in other countries, the current development in Germany points to a renewed increase in Sars-CoV-2 infections, according to the bulletin. From the beginning of the epidemic until Thursday, the RKI has registered 237,936 corona infections in Germany, including 9,285 deaths.